Cargando…
Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
Background: The Nuclear Factor of Activated T-cells 1 (NFATc1) transcription factor and the methyltransferase Enhancer of Zeste Homolog 2 (EZH2) significantly contribute to the aggressive phenotype of pancreatic ductal adenocarcinoma (PDAC). Herein, we aimed at dissecting the mechanistic background...
Autores principales: | Patil, Shilpa, Forster, Teresa, Reutlinger, Kristina, Kopp, Waltraut, Versemann, Lennart, Spitalieri, Jessica, Gaedcke, Jochen, Ströbel, Philipp, Singh, Shiv K., Ellenrieder, Volker, Neesse, Albrecht, Hessmann, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700089/ https://www.ncbi.nlm.nih.gov/pubmed/34943970 http://dx.doi.org/10.3390/cells10123463 |
Ejemplares similares
-
TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer
por: Versemann, Lennart, et al.
Publicado: (2022) -
NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression
por: Latif, Muhammad Umair, et al.
Publicado: (2022) -
Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer
por: Goetze, Robert G., et al.
Publicado: (2019) -
Aberrant NFATc1 signaling counteracts TGFβ-mediated growth arrest and apoptosis induction in pancreatic cancer progression
por: Hasselluhn, Marie C., et al.
Publicado: (2019) -
Cytosolic 5′-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites
por: Patzak, Melanie S., et al.
Publicado: (2019)